Soleno Therapeutics (SLNO) Operating Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Operating Expenses data on file, last reported at $63.3 million in Q1 2026.

• Quarterly Operating Expenses rose 38.44% year-over-year to $63.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.6 million (down 5.41% YoY) and the FY2025 annual result came in at $181.0 million, down 3.56% from the prior year.
• Operating Expenses grew to $63.3 million in Q1 2026 per SLNO's latest filing, from $52.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $80.2 million in Q3 2024 and bottomed at $5.6 million in Q4 2022.
• The 5-year median for Operating Expenses is $23.5 million (2024), against an average of $29.3 million.
• The widest annual swing landed in 2024, when Operating Expenses jumped 672.61%; it then sank 45.25% in 2025.
• Tracing SLNO's Operating Expenses over 5 years: stood at $5.6 million in 2022, then soared by 147.95% to $13.9 million in 2023, then jumped by 324.99% to $59.1 million in 2024, then decreased by 11.78% to $52.2 million in 2025, then climbed by 21.42% to $63.3 million in 2026.
• Per Business Quant, the three latest SLNO Operating Expenses figures stand at $63.3 million (Q1 2026), $52.2 million (Q4 2025), and $43.9 million (Q3 2025).

Peer Comparison